Penumbra Inc
PEN
Company Profile
Business description
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Contact
One Penumbra Place
AlamedaCA94502
USAT: +1 510 748-3200
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
4,200
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,463.00 | 42.50 | 0.50% |
| CAC 40 | 7,380.74 | 67.18 | 0.92% |
| DAX 40 | 19,909.14 | 75.18 | -0.38% |
| Dow JONES (US) | 42,544.22 | 29.51 | -0.07% |
| FTSE 100 | 8,173.02 | 52.01 | 0.64% |
| HKSE | 19,770.72 | 289.23 | -1.44% |
| NASDAQ | 19,310.79 | 175.99 | -0.90% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,881.63 | 25.31 | -0.43% |
| S&P/ASX 200 | 8,199.60 | 40.50 | 0.50% |
| SSE Composite Index | 3,316.50 | 35.27 | -1.05% |